Last reviewed · How we verify

NCT05902117: CopSCA

Place of Copeptin-troponin Assay in the Elimination Diagnosis of Non-ST+ ACS

Completed NA Last updated 18 March 2025
What this trial tests

NA trial testing Troponin and Copeptin assay in Acute Myocardial Infarction in 270 participants. Completed in 28 February 2025.

Timeline
28 June 2023
Primary endpoint
28 February 2025
28 February 2025

Quick facts

Lead sponsorHôpital NOVO
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment270
Start date28 June 2023
Primary completion28 February 2025
Estimated completion28 February 2025
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital NOVO — full company profile →

Who can join

18 and older, any sex, with Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to demonstrate that a combined troponin and copeptin assay can exclude non-ST+ ACS in patients with chest pain less than 6 hours old.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Myocardial Infarction

Currently open trials in the same condition.

Other Hôpital NOVO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05902117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing